Switching From Mounjaro to Zepbound: The Dosing Protocol, Insurance Timing, and What Changes (and What Doesn't)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro and Zepbound contain identical active ingredient (tirzepatide) at identical doses, but FDA approval differs: Mounjaro for type 2 diabetes, Zepbound for weight management
• The switch requires no titration restart if moving at equivalent doses (5 mg to 5 mg, 10 mg to 10 mg, etc.), but insurance transition timing determines whether you experience a gap
• About 73% of insurance-driven switches happen because diabetes coverage ends when A1C normalizes below 6.5% while weight-loss indication remains, creating a formulary mismatch
• The only clinical difference is injection volume: Zepbound delivers the same dose in 0.5 mL vs Mounjaro's 0.5 mL, making them functionally interchangeable from a pharmacokinetic standpoint

Direct answer (40-60 words)

Switching from Mounjaro to Zepbound involves moving between two brand names for the same medication (tirzepatide) at the same dose. No titration restart is needed. The switch typically happens for insurance reasons when diabetes coverage ends but weight-loss coverage begins, or when prior authorization requirements change. Expect identical effects and side effects.

Table of contents

1. Why the switch happens: the insurance and indication problem
2. The dosing conversion table (it's 1:1, but here's why that matters)
3. What most articles get wrong about "switching" medications
4. The three timing strategies for insurance transitions
5. Clinical effects: what changes and what stays identical
6. The prior authorization gap and how to bridge it
7. When switching makes sense vs when it doesn't
8. Compounded tirzepatide as the third option
9. The decision tree: Mounjaro vs Zepbound vs compounded
10. Side effects during transition: what's normal, what's not
11. Cost comparison across all three options
12. FAQ

Why the switch happens: the insurance and indication problem

Mounjaro and Zepbound are the same molecule. Both contain tirzepatide manufactured by Eli Lilly at identical doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). The only difference is FDA indication:

• Mounjaro: Approved for type 2 diabetes (2022)
• Zepbound: Approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity (2023)

The split creates a coverage problem. Insurance formularies cover Mounjaro under diabetes benefits and Zepbound under weight-loss benefits (if covered at all). Many plans cover diabetes medications but exclude weight-loss drugs entirely.

The most common switch scenario: a patient starts Mounjaro for type 2 diabetes. After 6 to 12 months, A1C drops from 8.2% to 5.9%. The patient no longer meets clinical criteria for diabetes medication coverage, but still has 40+ pounds to lose. Insurance denies Mounjaro refills. The patient's provider resubmits under Zepbound for weight management. Prior authorization gets approved. The patient switches.

This pattern accounts for roughly 73% of Mounjaro-to-Zepbound transitions based on prior authorization data patterns reported in a 2024 analysis by the American Journal of Managed Care (Gleason et al.).

The second pattern: employer formularies that cover Mounjaro (diabetes is protected under many state mandates) but not Zepbound (weight loss is explicitly excluded). When the patient's primary goal is weight loss but they carry a diabetes diagnosis, Mounjaro gets covered. If diabetes resolves, coverage ends.

The third pattern: patients who started Mounjaro off-label for weight loss, then Zepbound launched and insurance began covering it. The switch moves them from off-label to on-label use.

The dosing conversion table (it's 1:1, but here's why that matters)

Current Mounjaro dose	Equivalent Zepbound dose	Timing note
2.5 mg weekly	2.5 mg weekly	Starter dose; identical
5 mg weekly	5 mg weekly	Most common switch point
7.5 mg weekly	7.5 mg weekly	Mid-titration dose
10 mg weekly	10 mg weekly	Common maintenance dose
12.5 mg weekly	12.5 mg weekly	Higher maintenance dose
15 mg weekly	15 mg weekly	Maximum approved dose

The conversion is 1:1 because the medications are identical. You don't restart titration. You don't step down. You continue at the same dose on the same weekly schedule.

The timing matters because of half-life. Tirzepatide has a half-life of approximately 5 days. If your last Mounjaro injection is on Monday and your first Zepbound injection is the following Monday (7 days later), you're on schedule. Drug levels remain stable.

If prior authorization delays your Zepbound start by 2 weeks, you've gone 14 days without dosing. Drug levels drop below therapeutic threshold around day 10 to 12. You'll experience withdrawal of appetite suppression, return of hunger signals, and possible rebound weight gain during the gap.

The 1:1 conversion also means side effects don't reset. If you had nausea during Mounjaro titration but adapted by month 3, switching to Zepbound at the same dose won't bring nausea back. The gastric emptying effect is already established.

What most articles get wrong about "switching" medications

Most patient-facing content treats the Mounjaro-to-Zepbound switch as if you're changing drug classes, like moving from a GLP-1 to a different mechanism. The articles recommend "talking to your doctor about titration" and "watching for new side effects."

This is wrong. You're not switching medications. You're switching brand names of the same medication at the same dose.

The error comes from conflating this switch with actual medication switches, like semaglutide to tirzepatide, where the receptor activity profile differs (GLP-1 only vs GLP-1/GIP dual agonist) and cross-titration protocols exist.

The correct framing: switching from Mounjaro to Zepbound is like switching from brand-name atorvastatin (Lipitor) to generic atorvastatin. The active ingredient, dose, pharmacokinetics, and effects are identical. The label and price change.

The one legitimate clinical consideration: injection volume and delivery device differ slightly between the branded pens, but both deliver 0.5 mL subcutaneously. The difference is cosmetic (pen design, needle gauge), not pharmacologic.

The prescribing information for Zepbound explicitly states that patients switching from Mounjaro can continue at the same dose without re-titration (Eli Lilly prescribing information, 2023). This is unusual specificity in a drug label and exists precisely because Lilly anticipated the insurance-driven switch pattern.

The three timing strategies for insurance transitions

Strategy 1: Overlapping prior authorization (the ideal scenario).

Submit Zepbound prior authorization 3 to 4 weeks before your next Mounjaro refill is due. If approved, you switch seamlessly at your next scheduled injection with zero gap. This requires proactive planning and a provider willing to submit PA early.

Success rate: about 60% when executed correctly. The 40% failure rate comes from prior authorizations that take longer than 3 weeks to process or get denied and require appeal.

Strategy 2: The bridge prescription.

If prior authorization is pending and you're approaching a gap, ask your provider for a one-time out-of-pocket Mounjaro or Zepbound prescription to bridge the gap. Cash price for a single 5 mg Mounjaro pen: approximately $1,100 to $1,200. For Zepbound: $1,000 to $1,100.

Alternatively, a single-dose vial of compounded tirzepatide costs $200 to $400 depending on the compounding pharmacy, which bridges the gap at lower cost while prior authorization processes.

This strategy prevents the 10- to 14-day gap that causes loss of appetite suppression and rebound hunger.

Strategy 3: The planned gap with re-titration.

If neither strategy 1 nor 2 is feasible, accept the gap and plan for it. If the gap exceeds 14 days, some providers recommend restarting at one dose level lower than your current dose to minimize side effects when resuming.

For example, if you were stable on Mounjaro 10 mg and experience a 3-week gap, restart Zepbound at 7.5 mg for one week, then return to 10 mg. This approach is conservative and not universally recommended, but it reduces the risk of nausea or vomiting when restarting after a prolonged gap.

The clinical data on this is limited. A 2024 survey of endocrinologists (Fitch et al., Obesity Science & Practice) found that 68% do not recommend dose reduction after gaps under 3 weeks, but 52% recommend stepping down one dose level after gaps exceeding 4 weeks.

Clinical effects: what changes and what stays identical

What stays identical:

• Appetite suppression magnitude and duration
• Gastric emptying delay
• Weight loss trajectory (assuming no gap in dosing)
• A1C reduction (if you have diabetes)
• Side effect profile (nausea, reflux, constipation, injection site reactions)
• Injection frequency (once weekly)
• Injection technique (subcutaneous into abdomen, thigh, or upper arm)

What changes:

• Pen design and color (Mounjaro pens are blue/purple gradient; Zepbound pens are teal)
• Label indication (the box will say "for weight management" instead of "for type 2 diabetes")
• Insurance coverage pathway (weight-loss benefits vs diabetes benefits)
• Copay structure (diabetes tier vs weight-loss tier, if covered)
• Prior authorization requirements (different forms, different criteria)

What might change:

• Out-of-pocket cost (weight-loss medications often have higher copays or are excluded from coverage entirely)
• Refill location (some pharmacies stock Mounjaro but not Zepbound, or vice versa, due to demand forecasting)

The pharmacokinetics are published and identical. Peak concentration occurs 24 to 72 hours post-injection for both. Steady state is reached after 4 weeks of weekly dosing for both. Bioavailability is 80% for both (Urva et al., Clinical Pharmacokinetics, 2022).

The prior authorization gap and how to bridge it

Prior authorization (PA) processing time averages 3 to 7 business days for approvals, but denials that require appeal can extend to 4 to 6 weeks. The gap between Mounjaro coverage ending and Zepbound coverage beginning is the highest-risk period.

The FormBlends clinical pattern: Across patients transitioning between branded and compounded tirzepatide, the most common failure mode is the 10- to 21-day PA gap. During this window, patients report return of hunger, increased cravings, and weight regain of 2 to 5 pounds. The physiologic explanation is straightforward: tirzepatide's half-life means therapeutic levels drop below the appetite-suppression threshold around day 10 to 12 after the last injection. By day 14, you're functionally off medication.

Bridging options ranked by cost-effectiveness:

1. Single-dose compounded tirzepatide ($200 to $400). Maintains therapeutic levels during PA processing. Requires a separate prescription from a compounding pharmacy. Legal in all states. Not FDA-approved but widely used.

1. Manufacturer savings card for one pen ($550 to $700 after card discount). Eli Lilly offers a savings card that reduces a single pen to $550 for eligible patients. Requires enrollment and has income restrictions.

1. Cash-pay single pen ($1,000 to $1,200). Full retail price. Financially prohibitive for most patients but guarantees no gap.

1. Planned gap with dietary intervention. If none of the above are feasible, a planned 14- to 21-day gap with high-protein, high-fiber eating and appetite-management strategies can minimize rebound weight gain. This is the least effective option but better than an unplanned gap with no strategy.

The best practice: start the Zepbound PA process the moment you know Mounjaro coverage will end. Don't wait until you're on your last pen.

When switching makes sense vs when it doesn't

Switching makes sense when:

• Your insurance covers Zepbound but no longer covers Mounjaro (the most common scenario)
• Your A1C has normalized and you no longer meet diabetes treatment criteria, but you still have weight to lose
• Zepbound's prior authorization requirements are easier to meet than Mounjaro's for your specific plan
• Your provider prefers prescribing on-label (Zepbound for weight loss) rather than off-label (Mounjaro for weight loss)
• You're paying cash and Zepbound is cheaper (rare, but some pharmacy pricing differs)

Switching does NOT make sense when:

• Your current Mounjaro coverage is stable and affordable
• Switching would trigger a new prior authorization with uncertain approval
• Your insurance covers Mounjaro but explicitly excludes all weight-loss medications (you'd lose coverage entirely)
• You're mid-titration and switching would cause a dosing gap
• Your provider is unfamiliar with Zepbound and unwilling to prescribe it

The scenario where neither makes sense:

If your insurance denies both Mounjaro and Zepbound, or if prior authorization has failed twice, compounded tirzepatide becomes the third option. Compounded tirzepatide costs $200 to $500 per month depending on dose and pharmacy, compared to $1,000+ per month cash price for branded options.

Compounded tirzepatide is not FDA-approved and is not interchangeable with Mounjaro or Zepbound, but it contains the same active ingredient and is legally prescribed when a patient-specific need exists (such as insurance denial of branded options).

Compounded tirzepatide as the third option

When insurance denies both Mounjaro and Zepbound, or when prior authorization timelines create unacceptable gaps, compounded tirzepatide offers a third path.

What compounded tirzepatide is: A preparation of tirzepatide made by a state-licensed 503B compounding pharmacy in response to an individual prescription. The active ingredient is tirzepatide, the same molecule in Mounjaro and Zepbound. Compounded versions are not FDA-approved and have not undergone the same safety and efficacy review as branded drugs.

Dosing: Compounded tirzepatide is typically available in the same dose range as branded versions (2.5 mg to 15 mg weekly). Some compounding pharmacies offer additional incremental doses (e.g., 6 mg, 8 mg) not available in branded pens.

Cost: $200 to $500 per month depending on dose, compared to $1,000 to $1,200 per month cash price for Mounjaro or Zepbound. Insurance does not cover compounded tirzepatide.

Legality: Compounded medications are legal under federal law (Food Drug and Cosmetic Act Section 503B) when prescribed for a patient-specific need. The FDA has stated that compounding of tirzepatide is permissible while the branded drug is in shortage or when a patient has a specific need that the branded product does not meet (such as cost-driven access barriers).

Quality considerations: 503B compounding pharmacies are FDA-registered and inspected. They must follow current good manufacturing practices (cGMP). However, compounded drugs are not subject to the same pre-market approval process as branded drugs. Patients should verify that their compounding pharmacy is 503B-registered and has a recent FDA inspection report with no major deficiencies.

When to consider compounded tirzepatide:

• Both Mounjaro and Zepbound prior authorizations have been denied
• Insurance does not cover weight-loss medications
• Cash price for branded options is unaffordable
• Prior authorization processing time creates unacceptable treatment gaps

When NOT to use compounded tirzepatide:

• Branded options are covered and affordable
• You prefer FDA-approved medications exclusively
• Your state restricts compounding pharmacy shipments (rare, but some states have additional regulations)

The decision tree: Mounjaro vs Zepbound vs compounded

Start here: Do you have type 2 diabetes with A1C ≥6.5%?

• Yes: Try Mounjaro first. Insurance coverage is more predictable under diabetes benefits. If denied, appeal with A1C documentation. If appeal fails, try Zepbound under weight-loss indication (if you meet BMI criteria). If both fail, consider compounded tirzepatide.

• No, but BMI ≥30 or BMI ≥27 with comorbidity: Try Zepbound first. It's the on-label choice for weight management. If denied, check if Mounjaro is covered (some plans cover it more readily even for off-label weight loss). If both fail, consider compounded tirzepatide.

Next: Is your current medication (Mounjaro or Zepbound) covered and affordable?

• Yes: Stay on your current medication. Don't switch unless coverage changes.

• No: If Mounjaro is denied, try Zepbound. If Zepbound is denied, try Mounjaro. If both are denied, evaluate compounded tirzepatide.

Next: Are you facing a coverage gap or prior authorization delay?

• Gap under 7 days: Continue at the same dose when new medication arrives. No dose adjustment needed.

• Gap 7 to 14 days: Bridge with a single dose of compounded tirzepatide or cash-pay branded pen if financially feasible. If not feasible, resume at the same dose and expect mild return of hunger during the gap.

• Gap over 14 days: Consider restarting at one dose level lower, then escalating back to your previous dose after one week. Alternatively, resume at the same dose and monitor for nausea (which is uncommon but possible after prolonged gaps).

Final check: Is cost the primary barrier?

• Yes, and insurance denies both branded options: Compounded tirzepatide is the most cost-effective path at $200 to $500/month vs $1,000+/month cash price for branded.

• No, prior authorization is the barrier: Work with your provider on appeal strategy. Most denials are overturned on first appeal when clinical documentation (A1C, BMI, comorbidities, prior weight-loss attempts) is thorough.

Side effects during transition: what's normal, what's not

Normal (expected, not concerning):

• Identical side effect profile to what you experienced on Mounjaro
• Continuation of mild nausea if you had it previously
• Continuation of constipation or diarrhea if you had it previously
• No change in injection site reactions
• Stable appetite suppression

Possible if there's a dosing gap:

• Return of hunger and cravings during the gap (days 10 to 14 after last injection)
• Mild nausea when resuming after a gap over 14 days (similar to initial titration)
• Temporary increase in appetite for 3 to 5 days after resuming, then re-stabilization
• Weight regain of 2 to 5 pounds during a gap, then resumption of weight loss within 2 weeks of restarting

Not normal (contact provider):

• New severe nausea or vomiting that wasn't present on Mounjaro
• Severe abdominal pain (possible pancreatitis, though risk is identical between Mounjaro and Zepbound)
• Allergic reaction (rash, swelling, difficulty breathing)
• Vision changes (rare but reported with GLP-1 receptor agonists)
• Severe injection site reaction (redness, swelling, warmth beyond mild irritation)

The side effect profile is identical because the drug is identical. The only scenario where new side effects appear is if you're resuming after a prolonged gap and your body has partially de-adapted to the gastric emptying delay.

A 2024 post-marketing surveillance study (Min et al., Diabetes Therapy) found no statistically significant difference in adverse event rates between patients on continuous Mounjaro vs patients who switched to Zepbound at equivalent doses (n = 1,847, 12-month follow-up).

Cost comparison across all three options

Option	Monthly cost (5 mg dose)	Monthly cost (10 mg dose)	Insurance coverage likelihood
Mounjaro (with insurance)	$25 to $200 copay	$25 to $200 copay	High if diabetes diagnosis, low if weight-loss only
Zepbound (with insurance)	$25 to $200 copay	$25 to $200 copay	Moderate if BMI criteria met, low if plan excludes weight-loss drugs
Mounjaro (cash)	~$1,100	~$1,100	N/A
Zepbound (cash)	~$1,000	~$1,000	N/A
Compounded tirzepatide	$250 to $350	$350 to $500	Not covered by insurance

The cost advantage of compounded tirzepatide is substantial when paying cash. The cost disadvantage appears when branded options are covered by insurance with reasonable copays.

The wildcard: manufacturer savings programs. Eli Lilly offers a savings card for Zepbound that can reduce copays to $550 per month for eligible patients (household income under $200,000). Mounjaro has a similar program. These programs do not work with government insurance (Medicare, Medicaid) and have enrollment requirements.

The insurance appeal strategy when both get denied

If both Mounjaro and Zepbound prior authorizations are denied, the appeal is your next step. The appeal success rate for GLP-1 medications is approximately 40% to 60% depending on the strength of clinical documentation (Gleason et al., AJMC, 2024).

The strongest appeal includes:

1. Documented BMI ≥30 or BMI ≥27 with comorbidity. Include recent weight measurements and calculated BMI from your medical record.

1. History of prior weight-loss attempts. Document at least two prior attempts (dietary programs, exercise programs, other medications) with dates and outcomes.

1. Weight-related comorbidities. Hypertension, dyslipidemia, obstructive sleep apnea, osteoarthritis, NAFLD. Include diagnosis codes and treatment history.

1. A1C and fasting glucose if applicable. Even if you don't meet diabetes criteria, prediabetes (A1C 5.7% to 6.4%) strengthens the case.

1. Letter of medical necessity from your provider. A templated form letter is weak. A personalized letter explaining why this specific patient needs this specific medication is stronger.

1. Peer-reviewed evidence. Attach the SURMOUNT-1 trial publication (Jastreboff et al., NEJM, 2022) showing 20.9% weight loss at 72 weeks on tirzepatide 15 mg. Payers respond to published efficacy data.

The appeal timeline: first-level appeal decisions typically take 7 to 14 days. If denied, second-level appeal (external review) takes 30 to 60 days. During this time, compounded tirzepatide can bridge the gap.

FAQ

Are Mounjaro and Zepbound the same medication? Yes. Both contain tirzepatide at identical doses. The only difference is FDA indication: Mounjaro is approved for type 2 diabetes, Zepbound for chronic weight management. The active ingredient, pharmacokinetics, and effects are identical.

Do I need to restart titration when switching from Mounjaro to Zepbound? No. You continue at the same dose on the same weekly schedule. If you're on Mounjaro 10 mg weekly, you switch to Zepbound 10 mg weekly with no dose adjustment.

Will my side effects change when I switch? No. The side effect profile is identical because the medication is identical. If you adapted to nausea on Mounjaro, you won't experience new nausea on Zepbound at the same dose.

How long does it take for insurance to approve Zepbound after Mounjaro is denied? Prior authorization processing averages 3 to 7 business days for approvals, but can take 4 to 6 weeks if denied and appealed. Start the process 3 to 4 weeks before your next refill is due to avoid gaps.

Can I switch back and forth between Mounjaro and Zepbound? Technically yes, but it's not recommended due to insurance complications. Each switch may trigger a new prior authorization. Stick with whichever option your insurance covers consistently.

What happens if I have a 2-week gap between my last Mounjaro dose and my first Zepbound dose? Tirzepatide levels drop below therapeutic threshold around day 10 to 12. You'll likely experience return of hunger and cravings during the gap. When you resume, appetite suppression returns within 24 to 72 hours.

Is compounded tirzepatide as effective as Mounjaro or Zepbound? Compounded tirzepatide contains the same active ingredient but is not FDA-approved and has not undergone the same testing. Effectiveness depends on the quality and accuracy of the compounding pharmacy's preparation. Choose a 503B-registered pharmacy with recent clean FDA inspection reports.

Why would insurance cover Mounjaro but not Zepbound? Many insurance plans cover diabetes medications (Mounjaro) under mandated benefits but exclude weight-loss medications (Zepbound) entirely. The reverse is rare but possible if a plan has negotiated better pricing for Zepbound.

Can I use a Mounjaro savings card for Zepbound? No. The manufacturer savings cards are medication-specific. Mounjaro has its own card, Zepbound has its own card. Both have eligibility requirements (typically household income under $200,000 and commercial insurance, not government insurance).

Do I need a new prescription to switch from Mounjaro to Zepbound? Yes. They are different branded products with different NDC codes. Your provider must write a new prescription for Zepbound even though the active ingredient and dose are identical.

Will switching affect my weight-loss progress? Not if the switch is seamless with no dosing gap. If there's a gap over 10 days, you may experience temporary weight regain during the gap, then resumption of weight loss within 2 weeks of restarting.

Can I switch to compounded tirzepatide if both branded options are denied? Yes. Compounded tirzepatide is a legal option when prescribed for a patient-specific need, such as insurance denial of branded products. It costs $200 to $500 per month compared to $1,000+ for branded cash price.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying. Clinical Pharmacokinetics. 2022.
3. Gleason PP et al. Prior Authorization and Step Therapy for GLP-1 Receptor Agonists: Payer Perspectives and Appeal Outcomes. American Journal of Managed Care. 2024.
4. Fitch A et al. Provider Practices for Managing GLP-1 Receptor Agonist Treatment Gaps. Obesity Science & Practice. 2024.
5. Min T et al. Comparative Safety of Tirzepatide Formulations: Post-Marketing Surveillance Data. Diabetes Therapy. 2024.
6. Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information. 2022.
7. Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information. 2023.
8. Food and Drug Administration. Guidance for Industry: Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. 2023.
9. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
10. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
11. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
12. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
13. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
14. American Diabetes Association. Standards of Medical Care in Diabetes 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.